|
|
https://mb.cision.com/Public/18595/3853663/8e6c1cb612bd7eec_800x800ar.png
UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa =
with Six Abstracts at SHSA 2023
=C2=B7 Results from the Phase 3 studies evaluating impact of bimekizumab on=
pain and healthrelated quality of life in moderate to severe hidradenitis=
suppurativa will be shared in two oral... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3849333/abafd0fc3e8a6257_800x800ar.png
Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved=
High Thresholds of Clinical Response in Hidradenitis Suppurativa
=C2=B7 Bimekizumab treatment resulted in clinically meaningful improvements=
in HiSCR50 and the more stringent endpoints HiSCR75, HiSCR90 and HiSCR100 =
vs. placebo at Week... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3849304/8d2c62abe5dd821c_800x800ar.png
UCB to Present New Bimekizumab Data in Hidradenitis Suppurativa, Psorias=
is and Psoriatic Arthritis at EADV 2023
Brussels Belgium, 9 October 2023 07:00 CEST =E2=80=93 UCB, a global bio=
pharmaceutical company, today announced that it will present new data on bi=
mekizumab at the 32nd European Academy of... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3841624/aabfbc07c8c57524_800x800ar.png
UCB announces approval of RYSTIGGO^=C2=AE rozanolixizumab and ZILBRYSQ=
^=C2=AE zilucoplan for the treatment of adult patients with generalized m=
yasthenia gravis in Japan
=C2=B7 Japanese Ministry of Health, Labour and Welfare MHLW approves two =
UCB treatments, RYSTIGGO^=C2=AE rozanolixizumab and... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3838073/9a3d34b572093cc3_800x800ar.png
UCB Provides Update on U.S. Regulatory Review of Bimekizumab
Brussels Belgium, 19 September 2023 =E2=80=93 Time 23:00 CEST =E2=80=93=
Regulated Information =E2=80=93 Inside Information =E2=80=93 UCB, a global=
biopharmaceutical company, today provided an update on the Biologics Licen=
se Application BLA for... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3835417/b827dbaf6a1a5101_800x800ar.png
UCB receives CHMP positive opinion of zilucoplan for the treatment of ad=
ults with generalized myasthenia gravis in Europe
=C2=B7 The Committee for Medicinal Products for Human Use CHMP positive o=
pinion^1 is based on the pivotal Phase 3 RAISE study in generalized myasthe=
nia gravis gMG in adult patients... Lire le communiqué |
|
| |
|
| |
|
|
https://mb.cision.com/Public/18595/3826229/a20389101dcaff00_800x800ar.png
UCB presents new data at 35th International Epilepsy Congress IEC high=
lighting important advancements across Fintepla^=C2=AE=E2=96=BCfenfluramin=
e oral solution and broader epilepsies portfolio
=C2=B7 9 abstracts showcase new data for fenfluramine^1 in rare epilepsies =
including latebreaking data on safety... Lire le communiqué |
|
| |
|
| |
